{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-043425","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.239739+00:00","generated_at":"2026-05-15T06:10:34.027541+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Structure Therapeutics appoints Matthew Lang as COO and General Counsel","bullets":["Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.","Equity grant: options for 223,776 ordinary shares (74,592 ADSs), time-based RSUs for 184,614 ordinary shares, and PSUs for 46,155 ordinary shares at target.","Former Chief Legal Officer at Metsera, where he helped guide the up to $10B Pfizer acquisition; also held exec roles at Lyell, Myovant, and Gilead.","Company advancing aleniglipron into Phase 3 for obesity; Lang to support operational foundation and strategic priorities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-043425","json":"https://secwatch.observer/filing/0001104659-26-043425.json","markdown":"https://secwatch.observer/filing/0001104659-26-043425.md","text":"https://secwatch.observer/filing/0001104659-26-043425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926043425/0001104659-26-043425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926043425/tm2611763d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:10:34.027541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}